CRISPR Therapeutics AG, a leading gene editing company, has announced the availability of up to $378,641,978 of its common shares for sale through an Open Market Sale AgreementSM with Jefferies LLC. The shares will be offered at market prices and sold on The Nasdaq Global Market under the ticker symbol 'CRSP'. The proceeds from the sale are intended to fund research and clinical development of pipeline candidates, platform extensions, manufacturing infrastructure, working capital, and general corporate purposes. The company has previously issued 1,642,636 common shares under the Sales Agreement and plans to use the additional funds to continue advancing its CRISPR/Cas9-based therapeutics, including the landmark CRISPR-based therapy, CASGEVY, which was approved in 2023.

CRISPR Therapeutics AG, a leading gene editing company, has announced the availability of up to $378,641,978 of its common shares for sale through an Open Market Sale AgreementSM with Jefferies LLC. The shares will be offered at market prices and sold on The Nasdaq Global Market under the ticker symbol 'CRSP'. The proceeds from the sale are intended to fund research and clinical development of pipeline candidates, platform extensions, manufacturing infrastructure, working capital, and general corporate purposes. The company has previously issued 1,642,636 common shares under the Sales Agreement and plans to use the additional funds to continue advancing its CRISPR/Cas9-based therapeutics, including the landmark CRISPR-based therapy, CASGEVY, which was approved in 2023.